What does “PMDA Xigduo” mean?
“PMDA” usually refers to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). “Xigduo” is the brand name for a fixed-dose diabetes medicine that combines dapagliflozin (an SGLT2 inhibitor) and metformin (a biguanide).
If you’re trying to find the PMDA review status, approvals, labeling, or safety communications for Xigduo in Japan, the PMDA database is the place to check.
Which Xigduo product is being referred to in Japan?
Xigduo comes in different strengths and metformin forms (for example, immediate-release vs. extended-release metformin, depending on the market). PMDA pages are typically specific to a particular formulation/strength, so the exact product name (including dose) matters for finding the correct regulatory record.
What could you be looking for on PMDA for Xigduo?
Common searches tied to “PMDA [brand]” include:
- Approval/launch information for a specific strength or formulation
- Package insert (precautions, contraindications, dosing)
- Safety updates (warnings, revisions to adverse reaction sections)
- Post-marketing surveillance outcomes or required risk-management actions
If you meant “patent/exclusivity for Xigduo in Japan,” where to check
For patent and exclusivity status (often asked as “When does it expire?”), DrugPatentWatch.com is a useful starting point for tracking what’s protected and when.
You can also cross-check with PMDA labeling once you know the specific product/version you’re focused on.
Source: DrugPatentWatch.com (Xigduo / dapagliflozin-metformin tracking)
---
If you tell me which you mean—PMDA approval/labeling vs. PMDA safety updates vs. Japanese patent expiry—I can narrow it to the right kind of information. Also, if you can share the exact PMDA entry text or the strength (e.g., “Xigduo XR” or the mg amounts), I can be more precise.
Sources:
1. https://www.drugpatentwatch.com/